Viewing data from:

XULANE

ANDA

ETHINYL ESTRADIOL; NORELGESTROMIN | A200910 | MYLAN TECHNOLOGIES INC

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Xulane (2023)

Total Spending

$811K

Total Claims

4,584

Beneficiaries

1,329

Avg Cost/Unit

$32.17

Spending Trend

$1.7M(2019)→$1.8M(2020)→$1.4M(2021)→$1.1M(2022)→$811K(2023)

YoY Change:-7.0%

5yr CAGR:-3.7%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

Products (1)

#001 — 0.035MG/24HR;0.15MG/24HR

0 patents0 exclusivities▴

FILM, EXTENDED RELEASE;TRANSDERMAL | Approved: Apr 16, 2014

No patent or exclusivity listings for this strength.